Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine Optimization for Oxygen Saturation Index in ELBW Infants
NCT07216365Phase 2Recruiting
- Sponsor
- University of Rochester
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of caffeine in neonatal apnea (2 arms), sponsored by University of Rochester. Primary endpoints: Average Oxygen Saturation Index at Day 56, Total Duration of Respiratory Support at 1 year and 14 more. Started Jul 2026; status: recruiting.
02
Drugs
caffeine
03
Conditions
neonatal apnea
Beyond the preview
Go deeper on NCT07216365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216365.